Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2019
Mar. 31, 2019
Current Assets    
Cash $ 21,268 $ 47,044
Accounts receivable, net 76,201 163,405
Inventory 101,524 78,737
Prepaids and other current assets 14,666 65,273
Total Current Assets 213,659 354,459
Property and equipment, net 331,323 452,048
Operating lease right-of-use assets, net 350,752
Equity investments 570,911 898,292
Goodwill (provisional) 1,941,149 1,941,149
Other asset 10,133 5,500
TOTAL ASSETS 3,417,927 3,651,448
Current Liabilities    
Accounts payable 659,682 278,546
Note Payable 25,000 25,000
Convertible note payable - related party 192,000
Convertible note payable - unrelated parties, net of debt discount of $153,170 at December 31, 2019 346,769
Derivative liability 234,058
Current portion of operating lease liabilities 89,136
Accrued expenses 472,131 70,720
Total Current Liabilities 2,018,776 374,266
Operating lease liabilities, net of current portion 261,616
Total Liabilities 2,280,392 374,266
Commitments and Contingencies
Stockholders' Equity    
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at December 31, 2019 (unaudited) and 2018 and March 31, 2019, respectively
Common stock; $0.00001 par value; 200,000,000 shares authorized: 14,100,956 issued and outstanding at December 31, 2019 (unaudited) and 13,397,110 at March 31, 2019 143 135
Additional paid in capital $ 7,321,615 $ 6,892,242
Common stock to be issued, 808,805 shares at December 31, 2019 (unaudited) and 408,805 shares at March 31, 2019 993,807 773,807
Accumulated deficit $ (8,086,293) $ (5,531,260)
Total Applied BioSciences Corp. Stockholders' Equity 229,272 2,134,924
Non-controlling equity 908,263 1,142,258
Total Stockholders' Equity 1,137,535 3,277,182
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 3,417,927 $ 3,651,448